期刊文献+

Triamcinolone-assisted Pars Plana Vitrectomy for Retinal Disease

Triamcinolone-assisted Pars Plana Vitrectomy for Retinal Disease
下载PDF
导出
摘要 Purpose:To determine whether triamcinolone acetonide (TA)staining facilitates posterior hyaloid removal in patients undergoing pars plana vitrectomy (PPV) for retinal disease.Methods: A triamcinolone acetonide(TA)-assisted vitrectomy was performed on patients with the following disease: proliferative diabetic retionpathy(5eyes), central retinal vein occlusion(5eyes), macuar hole (3eyes), and epiretinal membrane(2eyes). Eyes without apparent preoperative posterior vitreous detachment were enrolled in this study. After a core PPV, TA aqueous suspension (40 mg/ml) was injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloid separation and removal. The visual acuity, intraocular pressure (IOP), tamponade, corneal pathology, after-cataract, vitreous hemorrhage, and necessity for reoperation were thereafter examined for at least 3 months after surgery.Results: In all patients, the vitreous body was clearly seen by means of triamcinolone during surgery, and complete removal of posterior hyaloid was facilitated and confirmed.Retina was attached in 14 of 15 eyes, and vision acuity was improved in 9 of 15 eyes.Two eyes showed transient postoperative IOP elevation, 2 eyes had after cataract formation and 1eye had cataract progression. Vitreous hemorrhage occurred in 1 eye. No eye had corneal pathology.Conclusion: Triamcinolone improved the visibility of the hyaloid and the safety of surgical procedures during PPV. No obvious adverse effect due to toxicity of TA accrued in TA-assisted PPV. Purpose: To determine whether triamcinolone acetonide (TA) staining facilitates posterior hyaloid removal in patients undergoing pars plana vitrectomy (PPV) for retinal disease.Methods : A tnamcmolone acetonide (TA)-ass]steo vitrectomy was pertormeu on patients with the following disease: proliferative diabetic retionpathy (Seyes), central retinal vein occlusion(Seyes), macuar hole (3eyes), and epiretinal membrane(2eyes). Eyes without apparent preoperative posterior vitreous detachment were enrolled in this study. After a core PPV, TA aqueous suspension (40 mg/ml) was injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloid separation and removal. The visual acuity, intraocular pressure (IOP), tamponade, corneal pathology, after-cataract, vitreous hemorrhage, and necessity for reoperation were thereafter examined for at least 3 months after surgery.Results: In all patients, the vitreous body was clearly seen by means ot triamcinolone during surgery, and complete removal of posterior hyaloid was facilitated and confirmed. Retina was attached in 14 of 15 eyes, and vision acuity was improved in 9 of 15 eyes. Two eyes showed transient postoperative IOP elevation, 2 eyes had after cataract formation and leye had cataract progression. Vitreous hemorrhage occurred in 1 eye. No eye had corneal pathology.Conclusion: Triamcinolone improved the visibility of the hyaloid and the safety of surgical procedures during PPV. No obvious adverse effect due to toxicity of TA accrued in TA-assisted PPV.
出处 《Eye Science》 CAS 2005年第3期142-146,共5页 眼科学报(英文版)
关键词 氟羟氢化泼尼松 玻璃体切除术 视网膜疾病 角膜移植 治疗方法 triamcinolone acetonide pars plana vitrectomy posterior vitreous separation
  • 相关文献

参考文献12

  • 1Davis MD. Vitreous contraction in proliferative diabetic retinopathy. Arch Ophthalmol, 1965 ; 74 : 741-751.
  • 2Takahashi M, Trempe CL, Maguire K, et al. Vitreoretinal relationship in diabetic retinopathy: a biomicroscopic evaluation. Arch Ophthalmol, 1981 ;99,241-245.
  • 3Peyman GA, Cheema R, Conway MD, et al. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina, 2000; 20: 554-555.
  • 4Anteliff RJ, Spalton DJ, Stanford MR, et al., Intravitreal triamcinolone for uveitic cystoid maeular edema: An optical coherence tomography study.Ophthalmology, 2001 ; 108 : 765-772.
  • 5Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol, 2002 ; 86 : 247-248.
  • 6Jonas JB, Sofker A. Intraoeular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. A m J Ophthalmol, 2001 ; 132 : 425-427.
  • 7Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triameinolone for cystoid macular edema in uveitis. Clin Exp Ophthalmol,2001 ;29:2-6.
  • 8Wingate R J, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. A ust N Z J Ophthalmol, 1999; 27 : 431-432.
  • 9Jonas JB, Hayler JK, Sofker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. A m J Ophthalmol, 2001 ; 131:468-471.
  • 10Nishimura A, Kobayashi A, Segawa Y, et al. Isolating triameinolone acetonide particles for intravitreal use with a porous membrane filter. Retina,2003 : 23 (6):777-779.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部